Myovant Sciences Ltd. NYSE:MYOV

Financial Health
0
1
2
3
4
5
6
7
8
9

Myovant Sciences Ltd. stock price monthly change

+0.26%
month

Myovant Sciences Ltd. stock price quarterly change

+0.71%
quarter

Myovant Sciences Ltd. stock price yearly change

+118.99%
year

Myovant Sciences Ltd. key metrics

Market Cap
2.62B
Enterprise value
2.72B
P/E
-14.05
EV/Sales
7.19
EV/EBITDA
-19.43
Price/Sales
6.89
Price/Book
-4.68
PEG ratio
-0.65
EPS
-2.21
Revenue
230.97M
EBITDA
-183.89M
Income
-205.98M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-48.47%
Oper. margin
-38.75%
Gross margin
73.03%
EBIT margin
-38.75%
EBITDA margin
-79.62%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Myovant Sciences Ltd. stock price history

Myovant Sciences Ltd. stock forecast

Myovant Sciences Ltd. financial statements

Myovant Sciences Ltd. (NYSE:MYOV): Profit margin
Jun 2021 41.06M -61.66M -150.16%
Sep 2021 77.90M -21.59M -27.72%
Dec 2021 54.44M -63.44M -116.54%
Mar 2022 57.56M -59.28M -102.98%
Myovant Sciences Ltd. (NYSE:MYOV): Earnings per share (EPS)
2022-10-26 -0.45266 -0.47
Myovant Sciences Ltd. (NYSE:MYOV): Debt to assets
Mar 2022 520011000 993.48M 191.05%
Jun 2022 460130000 943.65M 205.08%
Sep 2022 483974000 997.22M 206.05%
Dec 2022 403521000 961.66M 238.32%
Myovant Sciences Ltd. (NYSE:MYOV): Cash Flow
Jun 2021 -113.17M -74.39M 4.13M
Sep 2021 36.59M -13.38M 11M
Dec 2021 -91.89M 27.46M 4.00M
Mar 2022 -100.08M 42.28M 6.76M

Myovant Sciences Ltd. alternative data

Myovant Sciences Ltd. (NYSE:MYOV): Employee count
Aug 2023 579
Sep 2023 579
Oct 2023 579
Nov 2023 579
Dec 2023 579
Jan 2024 579
Feb 2024 579
Mar 2024 579
Apr 2024 579
May 2024 579
Jun 2024 579
Jul 2024 579

Myovant Sciences Ltd. other data

Myovant Sciences Ltd. (NYSE:MYOV): Insider trades (number of shares)
Period Buy Sel
Apr 2022 0 48635
May 2022 0 1382
Jul 2022 0 22866
Aug 2022 0 31214
Sep 2022 0 9243
Oct 2022 0 22813
Dec 2022 0 2241
Jan 2023 0 17456
Mar 2023 51599200 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
SUMITOMO CHEMICAL CO., LTD. 10 percent owner
Common Shares 51,599,200 $27 $1,393,178,400
Sale
LANG MATTHEW officer: General .. Common Shares 1,272 $26.89 $34,204
Sale
ARJONA FERREIRA JUAN CAMILO officer: Chief Medical Officer
Common Shares 1,109 $26.89 $29,821
Sale
MAREK DAVID C director, officer.. Common Shares 8,037 $26.89 $216,115
Sale
MAREK DAVID C director, officer.. Common Shares 8,037 $26.89 $216,115
Sale
MERENDINO LAUREN officer: Chief Commercial Officer
Common Shares 2,008 $26.89 $53,995
Sale
LANG MATTHEW officer: General .. Common Shares 2,779 $26.9 $74,755
Sale
ARJONA FERREIRA JUAN CAMILO officer: Chief Medical Officer
Common Shares 2,251 $26.9 $60,552
Sale
MEHRA UNEEK officer: Principal Financial Of..
Common Shares 2,241 $26.75 $59,947
Sale
MERENDINO LAUREN officer: Chief Commercial Officer
Common Shares 1,703 $25.2 $42,916
Saturday, 11 November 2023
prnewswire.com
Friday, 3 November 2023
prnewswire.com
Wednesday, 25 October 2023
prnewswire.com
Tuesday, 17 October 2023
prnewswire.com
Monday, 9 October 2023
prnewswire.com
Friday, 29 September 2023
prnewswire.com
Thursday, 26 January 2023
Zacks Investment Research
Wednesday, 26 October 2022
Zacks Investment Research
Monday, 24 October 2022
Pulse2
GlobeNewsWire
InvestorPlace
Benzinga
Market Watch
Friday, 14 October 2022
GlobeNewsWire
Friday, 7 October 2022
Seeking Alpha
Tuesday, 4 October 2022
Seeking Alpha
Monday, 3 October 2022
The Motley Fool
Invezz
Schaeffers Research
InvestorPlace
Investors Business Daily
Market Watch
Tuesday, 20 September 2022
Seeking Alpha
Friday, 2 September 2022
GlobeNewsWire
Monday, 29 August 2022
Seeking Alpha
Wednesday, 27 July 2022
Seeking Alpha
Monday, 18 July 2022
Seeking Alpha
Wednesday, 13 July 2022
GlobeNewsWire
Monday, 20 June 2022
Zacks Investment Research
Friday, 3 June 2022
GlobeNewsWire
  • When is Myovant Sciences Ltd.'s next earnings date?

    Unfortunately, Myovant Sciences Ltd.'s (MYOV) next earnings date is currently unknown.

  • Does Myovant Sciences Ltd. pay dividends?

    No, Myovant Sciences Ltd. does not pay dividends.

  • How much money does Myovant Sciences Ltd. make?

    Myovant Sciences Ltd. has a market capitalization of 2.62B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 289.39% to 230.97M US dollars. Myovant Sciences Ltd. made a loss 205.98M US dollars in net income (profit) last year or -$0.47 on an earnings per share basis.

  • What is Myovant Sciences Ltd.'s stock symbol?

    Myovant Sciences Ltd. is traded on the NYSE under the ticker symbol "MYOV".

  • What is Myovant Sciences Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Myovant Sciences Ltd.?

    Shares of Myovant Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Myovant Sciences Ltd.'s key executives?

    Myovant Sciences Ltd.'s management team includes the following people:

    • Mr. David C. Marek Chief Executive Officer & Director(age: 60, pay: $1,310,000)
    • Mr. Matthew Lang J.D. Gen. Counsel & Corporation Sec.(age: 49, pay: $1,030,000)
  • How many employees does Myovant Sciences Ltd. have?

    As Jul 2024, Myovant Sciences Ltd. employs 579 workers.

  • When Myovant Sciences Ltd. went public?

    Myovant Sciences Ltd. is publicly traded company for more then 8 years since IPO on 27 Oct 2016.

  • What is Myovant Sciences Ltd.'s official website?

    The official website for Myovant Sciences Ltd. is myovant.com.

  • How can i contact Myovant Sciences Ltd.?

    Myovant Sciences Ltd. can be reached via phone at +44 20 7400 3351.

Myovant Sciences Ltd. company profile:

Myovant Sciences Ltd.

myovant.com
Exchange:

NYSE

Full time employees:

579

Industry:

Biotechnology

Sector:

Healthcare

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

11-12 St. James’s Square
London, SW1Y 4LB

CIK: 0001679082
ISIN: BMG637AM1024
CUSIP: G637AM102